Korro Bio, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-09-30 was $2.00K, a 96.49% decline year-over-year.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $0.00.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $31.00K, a 77.70% decline year-over-year.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-12-31 was $0.00.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $196.00K, a 226.67% increase from fiscal 2021.
- Korro Bio, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $60.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-02 | $33.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $88.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $31.00K 10-Q · filed 2023-05-12 | $88.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $196.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | $57.00K 10-Q · filed 2023-11-02 | $195.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $199.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $139.00K 10-Q · filed 2023-05-12 | |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $60.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $61.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |